Lactase dehydrogenase as a tumor marker for recurrent disease in Ewing's sarcoma
Authors:
Abstract
The serum lactase dehydrogenase (LDH) of 56 patients with Ewing's sarcoma was examined to determine the use of LDH as a tumor marker. The initial LDH level was used to determine its ability to predict survival. The follow-up LDH level also was examined, as an indicator of recurrent disease. The initial LDH level was found to have no prognostic value. Both patients with elevated and normal LDH levels had the same survival rate. The LDH level at recurrence was significantly higher, however, than the follow-up LDH level of those without recurrence (P < 0.001). The LDH level was most sensitive as a tumor marker for recurrent disease in those patients with multiple sites of tumor involvement at the time of recurrence.Keywords
This publication has 14 references indexed in Scilit:
- Elevation of serum lactic dehydrogenase levels as an early marker of occult malignant lymphomaCancer, 1984
- Ewing's sarcoma: Ten-year experience with adjuvant chemotherapyCancer, 1981
- Biochemical Markers in Lymphoid MalignancyNew England Journal of Medicine, 1980
- Prognostic significance of serum lactate dehydrogenase in malignant lymphomaCancer, 1980
- Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcomaCancer, 1980
- Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomasBlood, 1979
- Automated determination of NAD-coupled enzymes. Determination of lactic dehydrogenaseAnalytical Biochemistry, 1965
- Serial Lactic Dehydrogenase Activity in Plasma of Mice with Growing or Regressing TumorsScience, 1960
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Versuche an Überlebendem Carcinom-gewebeJournal of Molecular Medicine, 1923